{"id":"menacwy-crm-vaccine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"10-15","effect":"Injection site erythema"},{"rate":"10-15","effect":"Injection site swelling"},{"rate":"20-30","effect":"Myalgia"},{"rate":"15-25","effect":"Headache"},{"rate":"15-25","effect":"Fatigue"},{"rate":"5-10","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y conjugated to CRM197 (a non-toxic diphtheria toxin variant), which enhances immunogenicity and T-cell dependent responses. This conjugation allows the vaccine to elicit both IgG antibodies and immunological memory, providing protection against invasive meningococcal disease caused by these four serogroups.","oneSentence":"MenACWY-CRM is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by coupling polysaccharide antigens to a carrier protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:39.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y"}]},"trialDetails":[{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT01725217","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-11","conditions":"Meningococcal Disease","enrollment":198},{"nctId":"NCT04440163","phase":"PHASE3","title":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":2431},{"nctId":"NCT03694405","phase":"PHASE4","title":"Adolescent MenACWY Booster Study","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-09-20","conditions":"Meningococcal Disease, Invasive","enrollment":244},{"nctId":"NCT02986854","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-08","conditions":"Infections, Meningococcal","enrollment":704},{"nctId":"NCT02287688","phase":"","title":"Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-01","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":144},{"nctId":"NCT01682876","phase":"PHASE3","title":"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-07","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":715},{"nctId":"NCT00329849","phase":"PHASE3","title":"Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-05","conditions":"Meningococcal Disease","enrollment":1500},{"nctId":"NCT00310856","phase":"PHASE2","title":"Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-06","conditions":"Meningococcal Meningitis","enrollment":175},{"nctId":"NCT01547715","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India","status":"COMPLETED","sponsor":"Novartis","startDate":"2012-03","conditions":"Bacterial Meningitis","enrollment":180},{"nctId":"NCT01214837","phase":"PHASE3","title":"Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-10","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":751},{"nctId":"NCT01766206","phase":"PHASE4","title":"Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-15","conditions":"Meningococcal Disease","enrollment":3948},{"nctId":"NCT00262041","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-10","conditions":"Prevention of Meningococcal Disease","enrollment":524},{"nctId":"NCT01345721","phase":"PHASE3","title":"Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-05","conditions":"Meningococcal Disease","enrollment":205},{"nctId":"NCT00856297","phase":"PHASE3","title":"Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-02","conditions":"Meningococcal Meningitis","enrollment":389},{"nctId":"NCT01453348","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-10","conditions":"Meningococcal Disease, Meningococcal Meningitis, Hepatitis A","enrollment":252},{"nctId":"NCT01705379","phase":"","title":"Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older","status":"WITHDRAWN","sponsor":"Novartis Vaccines","startDate":"2013-03","conditions":"Meningococcal Disease","enrollment":""},{"nctId":"NCT01593514","phase":"PHASE4","title":"Understanding the Immune Response to Two Different Meningitis Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-12","conditions":"Meningitis, Meningococcal Disease, Septicaemia","enrollment":20},{"nctId":"NCT01214850","phase":"PHASE3","title":"Novartis Vaccine and Diagnostics Carriage Trial","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"N. Meningitidis Carriage","enrollment":2968},{"nctId":"NCT00560313","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":54},{"nctId":"NCT00616421","phase":"PHASE3","title":"Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Meningococcal Infections","enrollment":2907},{"nctId":"NCT00262028","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-04","conditions":"Prevention of Meningococcal Disease","enrollment":910},{"nctId":"NCT00310817","phase":"PHASE2","title":"Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-03","conditions":"Meningococcal Meningitis","enrollment":623},{"nctId":"NCT01994629","phase":"PHASE2","title":"Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Meningococcal Disease","enrollment":202},{"nctId":"NCT01973218","phase":"PHASE3","title":"Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Meningococcal Disease","enrollment":264},{"nctId":"NCT01452438","phase":"","title":"Safety Surveillance of MenACWY-CRM Vaccine in Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-09","conditions":"Meningococcal Disease","enrollment":393},{"nctId":"NCT01018732","phase":"PHASE2","title":"A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-01","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":155},{"nctId":"NCT01452464","phase":"","title":"Safety of MenACWY-CRM Vaccination in Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-09","conditions":"Meningococcal Disease","enrollment":55397},{"nctId":"NCT00450437","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningococcal Infections, Meningococcal Meningitis","enrollment":3539},{"nctId":"NCT00488683","phase":"PHASE2","title":"B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":216},{"nctId":"NCT01410474","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-08","conditions":"Bacterial Meningitis","enrollment":341},{"nctId":"NCT01823536","phase":"PHASE4","title":"Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-05","conditions":"Meningococcal Disease","enrollment":465},{"nctId":"NCT00329901","phase":"PHASE3","title":"Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-04","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":1072},{"nctId":"NCT00262002","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-09","conditions":"Prevention of Meningococcal Disease","enrollment":601},{"nctId":"NCT00474487","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-05","conditions":"Meningococcal Meningitis, Meningococcal Infections","enrollment":2831},{"nctId":"NCT01000311","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-11","conditions":"Meningococcal Disease","enrollment":529},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT01466387","phase":"PHASE3","title":"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-11","conditions":"Meningococcal Disease, Meningococcal Meningitis, Typhoid","enrollment":552},{"nctId":"NCT01424644","phase":"PHASE4","title":"A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents","status":"COMPLETED","sponsor":"Novartis","startDate":"2011-09","conditions":"Meningococcal Meningitis","enrollment":801},{"nctId":"NCT00626327","phase":"PHASE3","title":"Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-02","conditions":"Meningococcal Infections","enrollment":1630},{"nctId":"NCT01274897","phase":"PHASE3","title":"A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-12","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MenACWY-CRM Vaccine","genericName":"MenACWY-CRM Vaccine","companyName":"Novartis","companyId":"novartis","modality":"Biologic","firstApprovalDate":"","aiSummary":"MenACWY-CRM is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by coupling polysaccharide antigens to a carrier protein. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}